Swedish Medical Center
Trial Pipeline
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
NCT07108660
Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma
NCT05380349
Early Chest Tube Removal After Surgery for Primary Spontaneous Pneumothorax: A Randomized Controlled Trial
NCT06411431
Minimally Invasive Esophagectomy Pain Control Trial
NCT05906134
Cancer Stem Cell High-Throughput Drug Screening Study
NCT02654964
Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer
NCT01241721
Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)
NCT01257880
Thymoglobulin: Presence and Affect in the Central Lymphatic Compartment
NCT00714480
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
NCT00430261
Phase II Trial of RAD001 in Refractory Colorectal Cancer
NCT00337545
Comparison of Laparoscopic Hill and Laparoscopic Nissen Anti-Reflux Procedures
NCT01260935
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Therapeutic Areas
What the Pipeline for Swedish Medical Center Shows
According to the ClinicalTrials.gov registry, Swedish Medical Center is linked to 11 US clinical trials across every stage of research activity. Of those, 4 studies are currently recruiting — about 36% of the sponsor's indexed portfolio — and 7 are already marked complete, representing roughly 64% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Swedish Medical Center reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 5 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Swedish Medical Center is Esophageal Reflux with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.